Patents by Inventor Douglas Richman

Douglas Richman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190025305
    Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced
    Type: Application
    Filed: December 11, 2017
    Publication date: January 24, 2019
    Applicant: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Patent number: 9841425
    Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: December 12, 2017
    Assignee: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Publication number: 20160209411
    Abstract: Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.
    Type: Application
    Filed: October 29, 2015
    Publication date: July 21, 2016
    Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Patent number: 9175355
    Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: November 3, 2015
    Assignee: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette Whitcomb, Wei Huang
  • Publication number: 20110033836
    Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced
    Type: Application
    Filed: December 10, 2009
    Publication date: February 10, 2011
    Applicant: MONOGRAM BIOSCIENCES, INC.
    Inventors: DOUGLAS RICHMAN, MARY T. WRIN, SUSAN LITTLE, CHRISTOS J. PETROPOULOS, NEIL T. PARKIN, JEANNETTE WHITCOMB, WEI HUANG
  • Patent number: 7247439
    Abstract: The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the a
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: July 24, 2007
    Assignee: Monogram Biosciences, Inc.
    Inventors: Douglas Richman, Mary T. Wrin, Susan Little, Christos J. Petropoulos, Neil T. Parkin, Jeannette M. Whitcomb, Wei Huang
  • Publication number: 20050214743
    Abstract: The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced i
    Type: Application
    Filed: February 14, 2003
    Publication date: September 29, 2005
    Inventors: Douglas Richman, Mary Wrin, Susan Little, Christos Petropoulos, Neil Parkin, Jeannette Whitcomb, Wei Huang
  • Publication number: 20030147870
    Abstract: The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
    Type: Application
    Filed: January 10, 2003
    Publication date: August 7, 2003
    Inventors: Eyal Raz, Hearn Jay Cho, Douglas Richman, Anthony A. Horner
  • Publication number: 20030143213
    Abstract: The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
    Type: Application
    Filed: January 10, 2003
    Publication date: July 31, 2003
    Inventors: Eyal Raz, Hearn Jay Cho, Douglas Richman, Anthony A. Horner
  • Patent number: 6534062
    Abstract: The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
    Type: Grant
    Filed: March 28, 2001
    Date of Patent: March 18, 2003
    Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Eyal Raz, Hearn Jay Cho, Douglas Richman, Anthony A. Horner
  • Publication number: 20020142977
    Abstract: The invention provides methods for T helper-independent activation of an antigen-specific cytotoxic T lymphocyte response in an individual. The methods generally involve administering to an individual an immunostimulatory nucleic acid molecule in an amount effective to increase an antigen-specific CTL response in the individual. The invention further provides methods for increasing chemokine secretion, which can block HIV infection.
    Type: Application
    Filed: March 28, 2001
    Publication date: October 3, 2002
    Inventors: Eyal Raz, Hearn Jay Cho, Douglas Richman, Anthony A. Horner